In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Lion Biotechnologies, Inc.. Trade Record

NASDAQ:LBIO Lion Biotechnologies, Inc. stock gains 33.46% Exit Mar 23, 2015 a Trade Record by priceseries

Trade Chart
Trade Chart LBIO Mar 9, 2015, priceSeries
About Lion Biotechnologies, Inc.

Lion Biotechnologies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) that is in Phase II clinical trial, which are T cells derived from patients' tumors for the treatment of patients with refractory metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health to develop, manufacture, and commercialize TIL therapies for the treatment of cervical, head and neck, bladder, lung, ovarian cancer, breast cancer, and colorectal cancers, as well as melanoma; cooperative research and development agreement with the National Institutes of Health and the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's tumor infiltrating lymphocytes; and manufacturing services agreement with Lonza Walkersville, Inc. and WuXi Apptech to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. The company was formerly known as Genesis Biopharma Inc. and changed its name to Lion Biotechnologies, Inc. in September 2013. Lion Biotechnologies, Inc. was founded in 2007 and is based in New York, New York.

Trade Information
Trade Type
LONG
ReliabilityScore™
46.73
Entry Date
Mar 9, 2015
Entry Price
9.14
Sell Date
Mar 23, 2015
Sell Price
12.20
Net Gain
33.46%
Hold Time
10 Trading Days